penicillamine has been researched along with Retinopathy of Prematurity in 22 studies
Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.
penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.
Retinopathy of Prematurity: A bilateral retinopathy occurring in premature infants treated with excessively high concentrations of oxygen, characterized by vascular dilatation, proliferation, and tortuosity, edema, and retinal detachment, with ultimate conversion of the retina into a fibrous mass that can be seen as a dense retrolental membrane. Usually growth of the eye is arrested and may result in microophthalmia, and blindness may occur. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare prophylactic enteral D-penicillamine (DPA) with placebo for prevention of 'retinopathy of prematurity (ROP) or death' among very low birth weight (VLBW) infants." | 9.14 | Oral D-penicillamine for the prevention of retinopathy of prematurity in very low birth weight infants: a randomized, placebo-controlled trial. ( Dogra, MR; Dutta, S; Gupta, A; Tandon, M, 2010) |
| "204 infants with birthweights between 751 and 2000 g and 26-35 weeks gestational age (100 treated and 104 control subjects) were enrolled in a prospective controlled trial of the effectiveness of D-penicillamine (DPA) in the prevention of retinopathy of prematurity (ROP)." | 9.06 | Controlled trial of D-penicillamine to prevent retinopathy of prematurity. ( Alaka, O; Balla, G; Hatvani, I; Karmazsin, L; Kincses, E; Lakatos, L; Lakatos, Z; Oroszlán, G; Szabó, I, 1986) |
| "We compared the development of retinopathy of prematurity (ROP) among 49 preterm neonates:; 15 who were treated during the first 2 weeks of life with D-penicillamine and 34 who were not." | 7.74 | D-Penicillamine administration and the incidence of retinopathy of prematurity. ( Alder, SC; Baer, VL; Barraza, J; Burnett, J; Christensen, RD; Horn, JT; Lambert, DK; Richards, M; Richards, SC; Schmutz, N; Wiedmeier, SE, 2007) |
| "We enterally administered a 14-day course of 3-mercapto-D-valine (D-penicillamine) to five extremely low birth weight (ELBW) neonates, as a step toward assessing this therapy as a means of reducing the incidence or severity of retinopathy of prematurity (ROP)." | 7.73 | A pilot trial testing the feasibility of administering D-penicillamine to extremely low birth weight neonates. ( Alder, SC; Baer, VL; Christensen, RD; Horn, JT; Lambert, DK; Richards, SC, 2006) |
| "To compare prophylactic enteral D-penicillamine (DPA) with placebo for prevention of 'retinopathy of prematurity (ROP) or death' among very low birth weight (VLBW) infants." | 5.14 | Oral D-penicillamine for the prevention of retinopathy of prematurity in very low birth weight infants: a randomized, placebo-controlled trial. ( Dogra, MR; Dutta, S; Gupta, A; Tandon, M, 2010) |
| "204 infants with birthweights between 751 and 2000 g and 26-35 weeks gestational age (100 treated and 104 control subjects) were enrolled in a prospective controlled trial of the effectiveness of D-penicillamine (DPA) in the prevention of retinopathy of prematurity (ROP)." | 5.06 | Controlled trial of D-penicillamine to prevent retinopathy of prematurity. ( Alaka, O; Balla, G; Hatvani, I; Karmazsin, L; Kincses, E; Lakatos, L; Lakatos, Z; Oroszlán, G; Szabó, I, 1986) |
| "D-penicillamine was introduced to treat neonatal hyperbilirubinaemia in 1973 and to prevent retinopathy of prematurity in 1980." | 4.78 | [D-penicillamine does not affect the liver and kidney function in newborn infants nor the in vitro function of phagocytes]. ( Csáthy, L; Lakatos, L; Maródi, L; Pataki, M; Szabó, I, 1991) |
| "To determine the effect of intraperitoneal and intravitreal D-penicillamine (DPA) on retinal neovascularization in a murine model of oxygen-induced retinopathy." | 3.77 | The effects of D-penicillamine on a murine model of oxygen-induced retinopathy. ( Ash, JD; Moreau, A; Siatkowski, RM; Yanovitch, TL, 2011) |
| "We compared the development of retinopathy of prematurity (ROP) among 49 preterm neonates:; 15 who were treated during the first 2 weeks of life with D-penicillamine and 34 who were not." | 3.74 | D-Penicillamine administration and the incidence of retinopathy of prematurity. ( Alder, SC; Baer, VL; Barraza, J; Burnett, J; Christensen, RD; Horn, JT; Lambert, DK; Richards, M; Richards, SC; Schmutz, N; Wiedmeier, SE, 2007) |
| "We enterally administered a 14-day course of 3-mercapto-D-valine (D-penicillamine) to five extremely low birth weight (ELBW) neonates, as a step toward assessing this therapy as a means of reducing the incidence or severity of retinopathy of prematurity (ROP)." | 3.73 | A pilot trial testing the feasibility of administering D-penicillamine to extremely low birth weight neonates. ( Alder, SC; Baer, VL; Christensen, RD; Horn, JT; Lambert, DK; Richards, SC, 2006) |
| "A prospective controlled trial has recently been reported to show the effectiveness of D-penicillamine (DPA) in the prevention of retinopathy of prematurity (ROP) among infants less than 2000 g birth-weight." | 3.67 | One year longitudinal follow-up of premature infants treated with D-penicillamine in the neonatal period. ( Itzés, B; Lakatos, L; Oroszlán, G; Vekerdy-Lakatos, S, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (50.00) | 18.7374 |
| 1990's | 3 (13.64) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 3 (13.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Qureshi, MJ | 1 |
| Kumar, M | 1 |
| Tandon, M | 1 |
| Dutta, S | 1 |
| Dogra, MR | 1 |
| Gupta, A | 1 |
| Siatkowski, RM | 1 |
| Yanovitch, TL | 1 |
| Ash, JD | 1 |
| Moreau, A | 1 |
| Christensen, RD | 2 |
| Alder, SC | 2 |
| Richards, SC | 2 |
| Horn, JT | 2 |
| Lambert, DK | 2 |
| Baer, VL | 2 |
| Vekerdy, Z | 2 |
| Lakatos, L | 16 |
| Balla, G | 4 |
| Oroszlan, G | 7 |
| Schmutz, N | 1 |
| Wiedmeier, SE | 1 |
| Burnett, J | 1 |
| Richards, M | 1 |
| Barraza, J | 1 |
| Hatvani, IL | 1 |
| Karmazsin, L | 6 |
| Makay, A | 1 |
| Hatvani, L | 1 |
| Hatvani, I | 4 |
| Phelps, DL | 4 |
| Matkovics, B | 1 |
| Watts, J | 1 |
| Watts, JL | 2 |
| Csáthy, L | 1 |
| Szabó, I | 3 |
| Pataki, M | 1 |
| Maródi, L | 1 |
| Alaka, O | 1 |
| Kincses, E | 2 |
| Lakatos, Z | 1 |
| Vekerdy-Lakatos, S | 1 |
| Itzés, B | 1 |
| Olubunmi, A | 1 |
5 reviews available for penicillamine and Retinopathy of Prematurity
| Article | Year |
|---|---|
D-Penicillamine for preventing retinopathy of prematurity in preterm infants.
Topics: Chelating Agents; Humans; Infant, Newborn; Infant, Premature; Penicillamine; Randomized Controlled T | 2013 |
Neonatal oxygen toxicity and its prevention: D-penicillamine offers benefits without harmful side-effects.
Topics: Humans; Infant, Newborn; Oxygen; Oxygen Consumption; Penicillamine; Retinopathy of Prematurity; Vita | 1982 |
D-Penicillamine for preventing retinopathy of prematurity in preterm infants.
Topics: Chelating Agents; Humans; Infant, Newborn; Infant, Premature; Penicillamine; Retinopathy of Prematur | 2000 |
D-Penicillamine for preventing retinopathy of prematurity in preterm infants.
Topics: Chelating Agents; Humans; Infant, Newborn; Infant, Premature; Penicillamine; Randomized Controlled T | 2001 |
[D-penicillamine does not affect the liver and kidney function in newborn infants nor the in vitro function of phagocytes].
Topics: Humans; Hyperbilirubinemia; In Vitro Techniques; Infant, Newborn; Kidney; Liver; Penicillamine; Phag | 1991 |
3 trials available for penicillamine and Retinopathy of Prematurity
| Article | Year |
|---|---|
Oral D-penicillamine for the prevention of retinopathy of prematurity in very low birth weight infants: a randomized, placebo-controlled trial.
Topics: Administration, Oral; Double-Blind Method; Free Radical Scavengers; Humans; Infant, Newborn; Infant, | 2010 |
Controlled trial of D-penicillamine to prevent retinopathy of prematurity.
Topics: Clinical Trials as Topic; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; Penicillamine; | 1986 |
[Prevention of retinopathy of premature infants with D-penicillamine].
Topics: Clinical Trials as Topic; Gestational Age; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant | 1985 |
14 other studies available for penicillamine and Retinopathy of Prematurity
| Article | Year |
|---|---|
The effects of D-penicillamine on a murine model of oxygen-induced retinopathy.
Topics: Animals; Animals, Newborn; Chelating Agents; Disease Models, Animal; Humans; Infant, Newborn; Inject | 2011 |
A pilot trial testing the feasibility of administering D-penicillamine to extremely low birth weight neonates.
Topics: Birth Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; F | 2006 |
An international replication, and the need for long term follow up studies.
Topics: Adult; Humans; Infant, Newborn; Penicillamine; Randomized Controlled Trials as Topic; Reproducibilit | 2006 |
D-Penicillamine administration and the incidence of retinopathy of prematurity.
Topics: Bilirubin; Chelating Agents; Creatinine; Female; Humans; Incidence; Infant, Newborn; Male; Neutropen | 2007 |
Penicillamine and retinopathy of prematurity.
Topics: Humans; Infant, Low Birth Weight; Infant, Newborn; Penicillamine; Retinopathy of Prematurity | 1983 |
[Mechanism of action of penicillamine D in the neonatal period].
Topics: Age Factors; Animals; Birth Weight; Humans; Infant, Newborn; Jaundice, Neonatal; Penicillamine; Rats | 1983 |
Experimental data on the prevention of retrolental fibroplasia by D-penicillamine.
Topics: Animals; Antioxidants; Choroid; Humans; Infant, Newborn; Liver; Lung; Macrophages; Oxygen Consumptio | 1980 |
Penicillamine, vitreous proliferation, and retinopathy of prematurity.
Topics: Eye Injuries; Glucocorticoids; Humans; Infant, Newborn; Penicillamine; Retinopathy of Prematurity; V | 1982 |
Penicillamine, vitreous proliferation, and retinopathy of prematurity.
Topics: Humans; Infant, Newborn; Infant, Premature; Penicillamine; Retinopathy of Prematurity | 1982 |
D-penicillamine in the prevention of retrolental fibroplasia.
Topics: Cell Membrane; Free Radicals; Humans; Infant; Infant, Newborn; Jaundice, Neonatal; Lipid Peroxides; | 1982 |
Transgenic mice model of ocular neovascularization driven by vascular endothelial growth factor (VEGF) overexpression.
Topics: Animals; Disease Models, Animal; Endothelial Growth Factors; Humans; Infant, Newborn; Lymphokines; M | 1998 |
International replications, anyone?
Topics: Chelating Agents; Copper; Humans; Infant, Newborn; Infant, Premature; Penicillamine; Retinopathy of | 1999 |
D-penicillamine and retinopathy of prematurity.
Topics: Humans; Infant, Newborn; Penicillamine; Retinopathy of Prematurity | 1988 |
One year longitudinal follow-up of premature infants treated with D-penicillamine in the neonatal period.
Topics: Child Development; Follow-Up Studies; Growth; Hospitalization; Humans; Infant Mortality; Infant, New | 1987 |